TTHX1114(NM141) in Combination With DWEK/DSO

Phase 2 Study To Determine the Safety and Efficacy of TTHX1114(NM141) on the Regeneration and Migration of Corneal Endothelial Cells in Patients Undergoing DWEK/DSO

Open label, single-treatment, with a concurrent non-treatment control

Key Inclusion Criteria:

• Fuchs Endothelial Cell Dystrophy (FECD) diagnosed more than 6 months
• Scheduled for DWEK/DSO with a planned central descemetorhexis of approx 4 to 5 mm
• Subjects in Group 2 must have a stable Fellow Eye with adequate function

Key Exclusion Criteria:

• Secondary corneal/ocular pathology in the Study Eye
• Prior refractive surgery in the Study Eye
• Prior exposure to TTHX1114